nanoknife IRE for pancreatic cancer

714 Posts | Page(s): Prev 12...70 71 72 

RE: nanoknife IRE for pancreatic cancer

by PhilipJax on Thu Apr 20, 2017 02:47 AM

Quote | Reply

Preventing Death Due To Cachexia-Anorexia

Everyone,
          The National Cancer Institute estimates that 20% to 40% of cancer deaths are attributable to the wasting syndrome known as cachexia, which causes loss of appetite, lean body mass, body wasting, and which can lead to multiple organ failure.
          Identifying pre-cachexia is of crucial importance for effective intervention.
          Please study the following journal articles to learn how to treat this deadly condition.  Then, check the medical records to learn whether these measures are being used.  (The good care manager always gathers the latest records and keeps them on hand.).
          If the oncologist is not utilizing the anti-cachexia therapies, get one who will, and very quickly.  Dithering also kills; this is a battle against time.
          PhilipJax
>> http://jaxelection.altervista.org/pancreatic/CachexiaTreatme
>> http://jaxelection.altervista.org/pancreatic/Cachexia2014The
>> http://jaxelection.altervista.org/pancreatic/Nutrition2015Ge
>> http://jaxelection.altervista.org/pancreatic/Supplements2016
>> http://jaxelection.altervista.org/pancreatic/Cachexia2015Mec
>> http://www.cancernetwork.com/oncology-journal/evolving-appro , Italy
>> http://www.cancernetwork.com/oncology-journal/early-engageme

RE: nanoknife IRE for pancreatic cancer

by PhilipJax on Fri Apr 21, 2017 11:11 AM

Quote | Reply

New 2017 NCCN Guidelines for Pancreatic Adenocarcinoma

Everyone,
          NCCN has released its 2017 pancreatic clinical practice guidelines.  Every care manager should study the document carefully (and study the last two years of posts on this site).  The link is here.
http://jaxelection.altervista.org/pancreatic/NCCN1.2017Pancr
          The following is a list of NCCN features by page number:
> Pg-4, the new Evidence Block system
> Pg-42, The ranking of chemo regimens using Evidence Blocks.  Focus on the far-left column: Efficacy.
> Pg-46, Staging code.  Your overall-condition and biopsy reports should use this coding.
> Pg-47, Details of the disease and therapies.
> Pg-98, Indications for specific therapies.
> Pg-2, Oncology leaders who authored this guideline.
> Pg-6, Physician decision tree.  With the exception of IRE, your physicians should be following this decision tool.  Nearly half of treating physicians ignore these guidelines.  See
http://jaxelection.altervista.org/pancreatic/9_Pancreatic201
http://jaxelection.altervista.org/pancreatic/7_MDAnderson201
         PhilipJax

RE: nanoknife IRE for pancreatic cancer

by cdaley2 on Fri Apr 21, 2017 02:23 PM

Quote | Reply

Philip - this a an extremely important document, thank you so much for sending it along. It is shocking how much information some doctors hold back (or don't know). Chris

RE: nanoknife IRE for pancreatic cancer

by tallysis on Sat Apr 22, 2017 04:11 AM

Quote | Reply
I see not a mention of IRE! Am I missing something?
714 Posts | Page(s): Prev 12...70 71 72 
Subscribe to this message board discussion

Latest Messages

View More

We care about your feedback. Let us know how we can improve your CancerCompass experience.